Dermatology

In this EADV interview, Bunick touches on his team’s findings related to risk of VTE, MACE, and malignancy in patients with atopic dermatitis treated with upadacitinib for 6 years.

In this analysis, the long-term cardiovascular safety of upadacitinib treatment for atopic dermatitis was highlighted.

These new data, presented at EADV, highlight remibrutinib’s impact on specific IgG autoantibody levels in individuals with chronic spontaneous urticaria (CSU).

This EADV interview featured a discussion with Brittany Craiglow, MD, on the topic of developments in the field of alopecia areata treatment.

New data reveals ritlecitinib's long-term effectiveness for alopecia areata, showing significant hair regrowth and sustained benefits in patients.

In this EADV interview, Chovatiya highlights some of his session’s most notable takeaways regarding current treatments and new data in the atopic dermatitis space.

Chapman discussed the latest findings from a phase 3 study assessing PDT with 10% ALA in people with BCC.

This interview with Amy Paller, MD, highlights the significance of the approval of ruxolitinib for the treatment of pediatric atopic dermatitis.

This approval by the FDA of ruxolitinib cream for children aged 2-11 years atopic dermatitis follows recent positive clinical trial findings on the treatment.

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

New findings confirm delgocitinib cream's safety and efficacy for chronic hand eczema, marking a significant advancement in treatment options.

In this interview at EADV, Pasumarthi highlights her team’s late-breaking data on ritlecitinib’s use among patients with cicatricial alopecias.

New research highlights delgocitinib cream's effectiveness for treating chronic hand eczema in adolescents.

Discover how roflumilast foam transforms treatment for seborrheic dermatitis, showing effectiveness across diverse skin tones.

This analysis highlights the safety and efficacy of JAK3/TEC inhibition in cicatricial alopecias, presented at EADV.

These late-breaking data at EADV highlight predictive factors for early super response to treatment with bimekizumab for psoriasis.

New phase 2b data reveals temtokibart significantly improves atopic dermatitis symptoms in adult patients.

This interview segment highlights Song’s risankizumab data covered during the 2025 EADV Congress in Paris.

These HS-OBTAIN phase 2a trial data highlight the impacts of treatment with brivekimig on patients naïve to biologics with moderate-to-severe HS.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

New data reveals bimekizumab offers sustained disease control for hidradenitis suppurativa, improving patient quality of life for 3 years.

Icotrokinra outperforms deucravacitinib in achieving skin clearance for plaque psoriasis, offering a promising new oral treatment option.

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

Eingun James Song, MD, highlights recent phase 4 data on risankizumab for patients with moderate to severe scalp and genital psoriasis.